Federal health regulators decided to allow the resumption of the U.S. trial of a leading Covid-19 vaccine candidate from AstraZeneca Plc and the University of Oxford, the Wall Street Journal reported, citing a person familiar with the matter and materials reviewed by it.
Global coronavirus cases rose by more than 400,000 for the first time, a record one-day increase as much of Europe enacts new restrictions to curb the outbreak.
UCB is investing more than £1 billion ($1.29 billion) over five years to expand the company’s research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
Johnson & Johnson temporarily paused the company’s Covid-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest-profile efforts to contain the global pandemic.
The widely used BCG tuberculosis vaccine will be tested on frontline care workers in Britain for its effectiveness against Covid-19, researchers running the UK arm of a global trial said.
Oxford University will study whether the world’s best-selling prescription medicine adalimumab was an effective treatment for Covid-19 patients in the latest effort to repurpose existing drugs as potential coronavirus therapies.
Will the solitary path the United States is on, insulate it from further Covid-19 pandemic-related damage? Christopher Snyder, a professor of economics at Dartmouth University, believes the answer depends largely on the eventual vaccine’s level of efficacy.
Britain will host clinical trials where volunteers are deliberately infected with the new coronavirus to test the effectiveness of vaccine candidates, the Financial Times reported, citing people involved in the project.
Jeff Winton Associates, a full-service communications agency for the pharmaceutical, biotechnology and other life sciences industries, announced expansion into additional global markets through a new partnership with UK-based marketing communications firm Onyx Health.
The adverse events that led to a pause in trials evaluating AstraZeneca Plc’s Covid-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.
